AR074776A1 - Metodo para tratar la degeneracion macular; modulando el sistema inmunitario del paciente - Google Patents
Metodo para tratar la degeneracion macular; modulando el sistema inmunitario del pacienteInfo
- Publication number
- AR074776A1 AR074776A1 ARP090104945A ARP090104945A AR074776A1 AR 074776 A1 AR074776 A1 AR 074776A1 AR P090104945 A ARP090104945 A AR P090104945A AR P090104945 A ARP090104945 A AR P090104945A AR 074776 A1 AR074776 A1 AR 074776A1
- Authority
- AR
- Argentina
- Prior art keywords
- patient
- cell
- methyl
- macular degeneration
- formula
- Prior art date
Links
- 210000000987 immune system Anatomy 0.000 title abstract 3
- 208000002780 macular degeneration Diseases 0.000 title abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 5
- 239000003112 inhibitor Substances 0.000 abstract 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 abstract 3
- 206010064930 age-related macular degeneration Diseases 0.000 abstract 3
- 230000028993 immune response Effects 0.000 abstract 3
- DFZRDLPTLDGONC-UHFFFAOYSA-N 2-(3-fluorophenyl)-n-indol-1-yl-4-methylpyrimidine-5-carboxamide Chemical compound N=1C=C(C(=O)NN2C3=CC=CC=C3C=C2)C(C)=NC=1C1=CC=CC(F)=C1 DFZRDLPTLDGONC-UHFFFAOYSA-N 0.000 abstract 2
- 101150020741 Hpgds gene Proteins 0.000 abstract 2
- 239000002253 acid Substances 0.000 abstract 2
- 239000005557 antagonist Substances 0.000 abstract 2
- 210000000581 natural killer T-cell Anatomy 0.000 abstract 2
- 210000000822 natural killer cell Anatomy 0.000 abstract 2
- FJKKCRCBBAXLQZ-UHFFFAOYSA-N 2-[3-[6-[2-(2,4-dichlorophenyl)ethylamino]-2-methoxypyrimidin-4-yl]phenyl]-2-methylpropanoic acid Chemical compound C=1C(C=2C=C(C=CC=2)C(C)(C)C(O)=O)=NC(OC)=NC=1NCCC1=CC=C(Cl)C=C1Cl FJKKCRCBBAXLQZ-UHFFFAOYSA-N 0.000 abstract 1
- -1 3,4,5-trimethoxy-phenylamino Chemical group 0.000 abstract 1
- 208000005590 Choroidal Neovascularization Diseases 0.000 abstract 1
- 206010060823 Choroidal neovascularisation Diseases 0.000 abstract 1
- 208000008069 Geographic Atrophy Diseases 0.000 abstract 1
- 208000000208 Wet Macular Degeneration Diseases 0.000 abstract 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 abstract 1
- 210000003651 basophil Anatomy 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 210000004443 dendritic cell Anatomy 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 210000003979 eosinophil Anatomy 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 210000003714 granulocyte Anatomy 0.000 abstract 1
- 210000003630 histaminocyte Anatomy 0.000 abstract 1
- YNVKAENVJKEMOU-UHFFFAOYSA-N n-(5-fluoro-3-methylindol-1-yl)-4-methyl-2-pyridin-2-ylpyrimidine-5-carboxamide Chemical compound C12=CC=C(F)C=C2C(C)=CN1NC(=O)C(C(=N1)C)=CN=C1C1=CC=CC=N1 YNVKAENVJKEMOU-UHFFFAOYSA-N 0.000 abstract 1
- VJCLAPUACUQZOV-UHFFFAOYSA-N n-[[3-[5-(2-hydroxypropan-2-yl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]-2-pyridin-2-ylpyrimidine-5-carboxamide Chemical compound O1C(C(C)(O)C)=NC(C=2C=C(CNC(=O)C=3C=NC(=NC=3)C=3N=CC=CC=3)C=CC=2)=N1 VJCLAPUACUQZOV-UHFFFAOYSA-N 0.000 abstract 1
- 210000000440 neutrophil Anatomy 0.000 abstract 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-N phosphoric acid Substances OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 abstract 1
- 150000003016 phosphoric acids Chemical class 0.000 abstract 1
- 230000004044 response Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
En la presente memoria se proporcionan métodos para prevenir, tratar o aliviar una degeneración macular tal como degeneración macular seca, degeneración macular húmeda y degeneración macular asociada a la edad en un paciente. Reivindicación 1: Un método para prevenir, tratar o aliviar la neovascularización coroidal en un paciente, que comprende administrar al paciente una cantidad eficaz de un compuesto que modula el sistema inmunitario del paciente, en donde el sistema inmunitario tiene respuestas inmunes de tipo I y respuestas inmunes de tipo II, de tal modo que administrar el compuesto al paciente aumenta las respuestas inmunes de tipo I en el paciente comparado con las respuestas inmunes de tipo I en el paciente antes de la administración del compuesto. Reivindicación 2: El método de la reivindicación 1, en el que el compuesto se selecciona del grupo que consiste en: (a) un inhibidor de la multicinasa syk; (b) un inhibidor de hPGDS; y (c) un antagonista de DP. Reivindicación 3: El método de la reivindicación 2, en el que el inhibidor de la multicinasa syk se selecciona del grupo que consiste en éster mono-{6-[5-fluoro-2-(3,4,5-trimetoxi-fenilamino)-pirimidin-4-ilamino)-2,2-dimetil-3-oxo-2,3-dihidro-pirido[3,2-b][1,4]oxazin-4-ilmetílico} del ácido fosfórico, sal de ácido acético de fórmula (1) y 2-[4-(7-etil-5H-pirrolo[2,3-b]pirazin-6-il-fenil]-propan-2-ol de fórmula (2). Reivindicación 4: El método de la reivindicación 2, en el que el inhibidor de hPGDS se selecciona del grupo que consiste en: indol-1-ilamida del ácido 2-(3-fluoro-fenil)-4-metil-pirimidina-5-carboxílico de fórmula (3); 3-[5-(1-hidroxi-1-metil-etil)-1,2,4-oxadiazol-3-il]-bencilamida del ácido 2-piridin-2-il-pirimidina-5-carboxílico de fórmula (4); y (5-fluoro-3-metil-indol-1-il)amida del ácido 4-metil-2-piridin-2-il-pirimidina-5-carboxílico de fórmula (5). Reivindicación 5: El método de la reivindicación 2, en el que el antagonista de DP es ácido 2-(3-{6-[2-(2,4-dicloro-fenil)-etilamino]-2-metoxi-pirimidin-4-il}-fenil)-2-metil-propiónico, sal de ácido fosfórico de fórmula (6). Reivindicación 6: El método de cualquiera de las reivindicaciones 1-5, en el que el compuesto modula la actividad de un inmunocito en el paciente. Reivindicación 7: El método de la reivindicación 6, en el que el inmunocito es una célula asesina natural (célula NK), una célula T asesina natural (célula NKT), un mastocito, una célula dendrítica, un granulocito seleccionado del grupo que consiste en un eosinófilo, un basófilo y un neutrófilo, o cualquier combinación de los mismos.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13870508P | 2008-12-18 | 2008-12-18 | |
| FR0955794 | 2009-08-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR074776A1 true AR074776A1 (es) | 2011-02-09 |
Family
ID=41716610
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP090104945A AR074776A1 (es) | 2008-12-18 | 2009-12-17 | Metodo para tratar la degeneracion macular; modulando el sistema inmunitario del paciente |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20110301125A1 (es) |
| EP (2) | EP2653193A1 (es) |
| JP (1) | JP2012512895A (es) |
| KR (1) | KR20110097955A (es) |
| CN (1) | CN102316868A (es) |
| AR (1) | AR074776A1 (es) |
| AU (1) | AU2009335749A1 (es) |
| BR (1) | BRPI0922465A2 (es) |
| CA (1) | CA2747478A1 (es) |
| IL (1) | IL213550A0 (es) |
| MX (1) | MX2011006391A (es) |
| SG (2) | SG172106A1 (es) |
| TW (1) | TW201034675A (es) |
| UY (1) | UY32346A (es) |
| WO (1) | WO2010080563A2 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2170837B1 (en) * | 2007-06-29 | 2011-11-02 | Sanofi | Process for preparing 2-(3-{6-[2-(2,4-dichlorophenyl)-ethylamino]-2-methoxypyrimidin-4-yl)-phenyl)-2-methylpropionic acid |
| CN107875155A (zh) | 2009-10-08 | 2018-04-06 | 赛诺菲 | 苯基噁二唑衍生物在制备治疗变应性或炎性疾病的药物中的用途 |
| CN105126122A (zh) * | 2014-12-12 | 2015-12-09 | 中国人民解放军第四军医大学 | microRNA mimics用于制备治疗脉络膜新生血管药物的应用 |
| CN107519491B (zh) * | 2017-09-04 | 2020-08-25 | 无锡市人民医院 | Copb2抑制剂的用途 |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4921475A (en) | 1983-08-18 | 1990-05-01 | Drug Delivery Systems Inc. | Transdermal drug patch with microtubes |
| US5087240A (en) | 1983-08-18 | 1992-02-11 | Drug Delivery Systems Inc. | Transdermal drug patch with conductive fibers |
| US4879119A (en) | 1984-02-21 | 1989-11-07 | Yamanouchi Pharmaceutical Co., Ltd. | Patch |
| NL8720442A (nl) | 1986-08-18 | 1989-04-03 | Clinical Technologies Ass | Afgeefsystemen voor farmacologische agentia. |
| US5163899A (en) | 1987-03-20 | 1992-11-17 | Drug Delivery Systems Inc. | Transdermal drug delivery system |
| US5312325A (en) | 1987-05-28 | 1994-05-17 | Drug Delivery Systems Inc | Pulsating transdermal drug delivery system |
| GB8804164D0 (en) | 1988-02-23 | 1988-03-23 | Tucker J M | Bandage for administering physiologically active compound |
| US5008110A (en) | 1988-11-10 | 1991-04-16 | The Procter & Gamble Company | Storage-stable transdermal patch |
| US5088977A (en) | 1988-12-21 | 1992-02-18 | Drug Delivery Systems Inc. | Electrical transdermal drug applicator with counteractor and method of drug delivery |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| IE66203B1 (en) | 1989-12-04 | 1995-12-13 | Searle & Co | System for transdermal albuterol administration |
| WO1992016192A1 (en) | 1991-03-15 | 1992-10-01 | Amgen Inc. | Pulmonary administration of granulocyte colony stimulating factor |
| US5352456A (en) | 1991-10-10 | 1994-10-04 | Cygnus Therapeutic Systems | Device for administering drug transdermally which provides an initial pulse of drug |
| DE69228827T2 (de) | 1991-12-18 | 1999-10-21 | Minnesota Mining And Mfg. Co., Saint Paul | Mehrschichtige sperrstrukturen |
| ATE132381T1 (de) | 1992-01-29 | 1996-01-15 | Voelkl Franz Ski | Ballspielschläger, insbesondere tennisschläger |
| US5451569A (en) | 1994-04-19 | 1995-09-19 | Hong Kong University Of Science And Technology R & D Corporation Limited | Pulmonary drug delivery system |
| US6977283B1 (en) | 1998-04-07 | 2005-12-20 | Exxonmobil Chemical Patents Inc. | Polymerization process |
| EP0964361A1 (en) | 1998-06-08 | 1999-12-15 | International Business Machines Corporation | Protection of sensitive information contained in integrated circuit cards |
| ATE290837T1 (de) | 1999-10-21 | 2005-04-15 | Alcon Inc | Medikamentenversorgung der sub-tenon |
| US7273883B2 (en) * | 2000-09-14 | 2007-09-25 | Allergan, Inc. | Prostaglandin EP4 antagonist |
| IL161576A0 (en) | 2001-10-26 | 2004-09-27 | Aventis Pharma Inc | Benzimidazoles and analogues and their use as protein kinases inhibitors |
| US20050059639A1 (en) | 2003-09-11 | 2005-03-17 | Wei Edward T. | Ophthalmic compositions and method for treating eye discomfort and pain |
| US20060004043A1 (en) * | 2003-11-19 | 2006-01-05 | Bhagwat Shripad S | Indazole compounds and methods of use thereof |
| DOP2005000039A (es) | 2004-03-26 | 2005-10-31 | Aventis Pharma Inc | Hidrocloruro de [4-(5-aminometil-2-fluoro-fenil)- piperidin-1-il]-(4-bomo-3-metil-5-propoxi-tiofen-2-il)-metanona como un inhibidor de la triptasa de mastocitos |
| US20050234030A1 (en) * | 2004-04-20 | 2005-10-20 | Wilmin Bartolini | Modulators of CRTH2, COX-2 and FAAH |
| EP1740168A2 (en) * | 2004-04-21 | 2007-01-10 | Advanced Ocular Systems Limited | Antiprostaglandins for the treatment of ocular pathologies |
| HN2005000795A (es) * | 2004-10-15 | 2010-08-19 | Aventis Pharma Inc | Pirimidinas como antagonistas del receptor de prostaglandina d2 |
| CN101115761B (zh) | 2005-01-19 | 2012-07-18 | 里格尔药品股份有限公司 | 2,4-嘧啶二胺化合物的前药及其应用 |
| NZ567241A (en) * | 2005-09-30 | 2010-08-27 | Miikana Therapeutics Inc | Substituted pyrazole compounds |
| CN101316587B (zh) * | 2005-09-30 | 2013-04-03 | 迈卡纳治疗股份有限公司 | 取代的吡唑化合物 |
| GT200600457A (es) * | 2005-10-13 | 2007-04-27 | Aventis Pharma Inc | Sal de fosfato dihidrogeno como antagonistas del receptor de prostaglandina d2 |
| AR060403A1 (es) * | 2006-04-12 | 2008-06-11 | Sanofi Aventis | Compuestos de amino- pirimidina 2,6- sustituidos -4- monosustituidos como antagonistas del receptor de prostaglandina d2 |
| CL2007002617A1 (es) * | 2006-09-11 | 2008-05-16 | Sanofi Aventis | Compuestos derivados de pirrolo[2,3-b]pirazin-6-ilo; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar inflamacion de las articulaciones, artritis reumatoide, tumores, linfoma de las celulas del manto. |
| CN101528744A (zh) * | 2006-10-20 | 2009-09-09 | Irm责任有限公司 | 用于调节c-kit和pdgfr受体的组合物和方法 |
| EP2078026B1 (en) * | 2006-11-21 | 2012-01-04 | Rigel Pharmaceuticals, Inc. | Prodrug salts of 2, 4-pyrimidinediamine compounds and their uses |
| NZ587906A (en) | 2008-03-10 | 2011-12-22 | Sanofi Aventis | Treatment for ocular-related disorders |
| EA201100549A1 (ru) * | 2008-11-10 | 2011-12-30 | Пфайзер Лимитед | Пирролидины |
-
2009
- 2009-12-17 AR ARP090104945A patent/AR074776A1/es not_active Application Discontinuation
- 2009-12-17 TW TW098143262A patent/TW201034675A/zh unknown
- 2009-12-18 BR BRPI0922465A patent/BRPI0922465A2/pt not_active Application Discontinuation
- 2009-12-18 US US13/140,799 patent/US20110301125A1/en not_active Abandoned
- 2009-12-18 JP JP2011542460A patent/JP2012512895A/ja active Pending
- 2009-12-18 KR KR1020117016429A patent/KR20110097955A/ko not_active Withdrawn
- 2009-12-18 EP EP13176594.3A patent/EP2653193A1/en not_active Withdrawn
- 2009-12-18 AU AU2009335749A patent/AU2009335749A1/en not_active Abandoned
- 2009-12-18 WO PCT/US2009/068625 patent/WO2010080563A2/en not_active Ceased
- 2009-12-18 UY UY0001032346A patent/UY32346A/es unknown
- 2009-12-18 SG SG2011042868A patent/SG172106A1/en unknown
- 2009-12-18 EP EP09796895A patent/EP2370077A2/en not_active Withdrawn
- 2009-12-18 CN CN2009801572927A patent/CN102316868A/zh active Pending
- 2009-12-18 SG SG2013092796A patent/SG196770A1/en unknown
- 2009-12-18 MX MX2011006391A patent/MX2011006391A/es not_active Application Discontinuation
- 2009-12-18 CA CA2747478A patent/CA2747478A1/en not_active Abandoned
-
2011
- 2011-06-14 IL IL213550A patent/IL213550A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW201034675A (en) | 2010-10-01 |
| IL213550A0 (en) | 2011-07-31 |
| SG196770A1 (en) | 2014-02-13 |
| AU2009335749A1 (en) | 2011-07-07 |
| US20110301125A1 (en) | 2011-12-08 |
| CN102316868A (zh) | 2012-01-11 |
| BRPI0922465A2 (pt) | 2016-02-10 |
| KR20110097955A (ko) | 2011-08-31 |
| CA2747478A1 (en) | 2010-07-15 |
| MX2011006391A (es) | 2011-09-15 |
| WO2010080563A2 (en) | 2010-07-15 |
| UY32346A (es) | 2010-07-30 |
| EP2653193A1 (en) | 2013-10-23 |
| WO2010080563A3 (en) | 2010-08-26 |
| SG172106A1 (en) | 2011-07-28 |
| EP2370077A2 (en) | 2011-10-05 |
| JP2012512895A (ja) | 2012-06-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9765299B2 (en) | Chemically defined albumin-free conditions for cardiomyocyte differentiation of human pluripotent stem cells | |
| AR120109A1 (es) | Compuestos de pirido[3,2-d]pirimidina como inmunomoduladores | |
| NZ630719A (en) | Imidazo [1, 2 - b] pyridazine - based compounds, compositions comprising them, and uses thereof | |
| EA201490859A1 (ru) | Алкилированные соединения пиперазина в качестве ингибиторов тирозинкиназы брутона | |
| CO6612267A2 (es) | Nuevos derivados de 1,1 dióxido- 5 fenil- 2,3,4-5tetrahidro- 1,4-benzotiazepina y composiciones farmaceúticas que los comprenden | |
| NZ605627A (en) | Pyrrolo-pyrazine derivatives useful as inhibitors of atr kinase | |
| PE20190348A1 (es) | Moduladores de la via de estres integrada | |
| IN2014DN09221A (es) | ||
| ATE496045T1 (de) | Pyrimidinderivate als inhibitoren von phosphatidylinositol-3-kinase | |
| NZ630721A (en) | Pyrazolo[1,5-a]pyrimidine-based compounds, compositions comprising them, and methods of their use | |
| PE20141023A1 (es) | Derivados de (1,2,4) triazolo [4,3-a] quinoxalina como inhibidores de fosfodiesterasas | |
| CU20140023A7 (es) | DERIVADOS DE N-(3-(1,2,4-OXADIAZOL-3/5-IL)FENIL)IMIDAZO[1,2-a]PIRIDIN-3-CARBOXAMIDA COMO INHIBIDORES DE LA QUINASA c-Kit | |
| AR103283A1 (es) | 5-fluoro-4-imino-3-(alquil / alquilo sustituido)-1-(arilsulfonil)-3,4-dihidropirimidin-2(1h)-ona como tratamiento de semillas y plántulas | |
| AR077975A1 (es) | Derivados de pirazol pirimidina y composiciones como inhibidores de cinasa de proteina | |
| CO6630133A2 (es) | Compuestos de pirazol -4-il heterociclil -carboxamida y métodos de uso | |
| DOP2018000065A (es) | Derivados de 8-[6-[3-(amino)propoxi]-3-piridil]1-isopropilimidazo[4,5-c]quinolin-2-ona como moduladores selectivos de la cinasa de la ataxia telangiectasia mutada (atm) para el tratamiento del cáncer | |
| NZ599815A (en) | N1-pyrazolospiroketone acetyl-coa carboxylase inhibitors | |
| MX2012004311A (es) | Derivados de ciclohexano spiro condensados como inhibidores de lipasa sensible a hormonas (hsl) utiles en el tratamiento de diabetes. | |
| MX343160B (es) | Dicetopiperazinas para uso en inhibir hiperpermeabilidad vascular. | |
| RU2017105781A (ru) | Индазольные соединения в качестве ингибиторов киназы fgfr, их получение и применение | |
| AR101177A1 (es) | Inhibidores de la syk | |
| EA201490103A1 (ru) | Гидроксиметиларилзамещенные пирролотриазины в качестве ингибиторов alk1 | |
| UY39559A (es) | Compuestos y su uso | |
| AR065788A1 (es) | Composicion agricola para controlar o prevenir enfermedades de las plantas provocadas por microbios patogenos de las plantas | |
| NZ627361A (en) | 1h-pyrrolo[2,3-b] pyridine derivatives and their use as kinase inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |